IQGAP3 can Serve as a Promising Biomarker for the Diagnosis of Endometrial Cancer

Objective: Endometrial cancer (EC), a prevalent malignancy in women's reproductive system, commonly occurs in uterine tissue. Due to its persistently high incidence despite considerable medical advancements, there is a need for the identification of novel diagnostic and treatment biomarkers. This study aims to investigate the potential of IQ motif-containing GTPase-activating protein 3 (IQGAP3) as a biomarker for early diagnosis of endometrial cancer and explore its significance in cervical cancer. Methods: This study utilized CaSki and Hela cell lines and employed siRNA/shRNA and scrambled control antisense for transfection experiments. However, the expression level of the gene was assessed using qPCR (Quantitative Polymerase Chain Reaction). Additionally, the involvement of IQGAP3 in the cell cycle pathway was elucidated through pathway analysis. Results: Tumor Immune Estimation Resource (TIMER) 2.0 data analysis showed that IQGAP3 exhibited significant overexpression in cancer groups (* p < 0.05), with elevated levels in EC samples compared to normal tissues (*** p < 0.001). Furthermore, IQGAP3 showed significantly close association with survival prognosis ( p < 0.05). Additionally, we observed that the knockdown of IQGAP3 inhibited cell proliferation in endometrial cancer cells. Conclusion: This study provides valuable insights into the role of IQGAP3 in cancer diagnosis and treatment. The findings suggest that IQGAP3 holds potential as a promising biomarker for endometrial cancer diagnosis and as a therapeutic target for its treatment.